The antiarrhythmic effects of quaternary salts of beta-adrenergic blocking agents.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000779:Anesthetics, Local; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology; D005260:Female; D006221:Halothane; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D002040:Levobunolol / Q000494:pharmacology; D008297:Male; D009132:Muscles / Q000187:drug effects; D009578:Nitrobenzenes / Q000494:pharmacology; D009638:Norepinephrine; D010042:Ouabain / Q000037:antagonists & inhibitors / Q000633:toxicity; D010627:Phenethylamines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012584:Sciatic Nerve / Q000187:drug effects; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000779:Anesthetics, Local; D000889:Anti-Arrhythmia Agents; D004983:Ethanolamines; D009578:Nitrobenzenes; D010627:Phenethylamines; D010042:Ouabain; D011433:Propranolol; D002040:Levobunolol; D007545:Isoproterenol; D006221:Halothane; D009638:Norepinephrine